Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dabrafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 20/20 | 0.95 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.95 |
| ▸ | PLK4 | O00444 | 1/20 | 0.95 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.95 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.95 |
| ▸ | JAK2 | O60674 | 1/20 | 0.95 |
| ▸ | ULK1 | O75385 | 1/20 | 0.95 |
| ▸ | ERN1 | O75460 | 1/20 | 0.95 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.95 |
| ▸ | ABL1 | P00519 | 1/20 | 0.95 |
| ▸ | KRAS | P01116 | 1/20 | 0.95 |
| ▸ | RAF1 | P04049 | 1/20 | 0.95 |
| ▸ | LCK | P06239 | 1/20 | 0.95 |
| ▸ | FYN | P06241 | 1/20 | 0.95 |
| ▸ | CDK1 | P06493 | 1/20 | 0.95 |
| ▸ | YES1 | P07947 | 1/20 | 0.95 |
| ▸ | LYN | P07948 | 1/20 | 0.95 |
| ▸ | MET | P08581 | 1/20 | 0.95 |
| ▸ | HCK | P08631 | 1/20 | 0.95 |
| ▸ | FGR | P09769 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dabrafenib SCHEMBL1127269 | 1.00 | BRAF (0.95) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL806377 | 0.97 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29353365 | 0.97 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29350038 | 0.97 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL13739419 | 0.97 | BRAF (0.98) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL14733912 | 0.93 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL21425052 | 0.93 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL2193062 | 0.92 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL14733909 | 0.92 | BRAF (0.89) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL1127301 | 0.90 | BRAF (0.83) | BRAFNR1I2PLK4EPHB6RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3091 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-4695260-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4678173-A2 | TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USE | Spero Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-30 | — | — | US | claimed |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM INC (US) | 2025-12-04 | — | — | US | claimed |
| EP-3986463-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| EP-3986476-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| WO-2022036024-A9 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| US-20220096518-A1 | COMPOSITIONS AND METHODS FOR CANCER THERAPY | AIM IMMUNOTECH INC. (US) | 2022-03-31 | — | — | US | claimed |
| WO-2022020655-A9 | METHOD FOR TREATING MELANOMA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-03-17 | — | — | WO | claimed |
| EP-3092232-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE AGAINST CANCER AND VIRAL INFECTIONS | SAGIMET BIOSCIENCES INC (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2022046947-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF A VARIANT | GUARDANT HEALTH, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| WO-2022036024-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| WO-2022031476-A2 | METHODS AND COMPOSITIONS FOR PROTEASE REPORTER ASSAYS AND MODULATORS | 712 NORTH, INC. (US) | 2022-02-10 | — | — | WO | claimed |